Your browser doesn't support javascript.
loading
Latest in COVID-19 Vaccine 'Candidates' Race.
Atoum, Manar Fayiz; Zreig, Dalia Abu; Abu Zreig, Laith Majed.
Afiliação
  • Atoum MF; Faculty of Applied Health Sciences, Medical Laboratory Science, Hashemite University, Zarqa, Jordan.
  • Zreig DA; Faculty of Medicine, Jordan University of Science and Technology, Ar-Ramtha, Jordan.
  • Abu Zreig LM; Faculty of Medicine, Ophthalmology, Jordan University of Science and Technology, Jordan.
Infect Disord Drug Targets ; 23(1): e180822207640, 2023.
Article em En | MEDLINE | ID: mdl-35984031
Restoring everyday civil life from the devastating pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be only by the development of an efficient vaccine. As of April 12, 2022, 497,960,492 confirmed cases of COVID-19 were reported, including 6,181,850 lives having been lost worldwide and completely paralyzing the d global economy. Detection of a novel coronavirus SARS-CoV-2 in Wuhan, in December 2019, and the genetic sequence of SARS-CoV-2 that was published on January 11, 2020, leads to a global race, to prepare for a preventive vaccine. No single institution can develop a vaccine individually because there are many stages for developing and producing a successful vaccine. Since this virus threatens the health, the economy, and society the demand for a fast-track vaccine is understandable. This article tries to give an overview of vaccine 'candidates' development and clinical trials, and it mentions some challenges of using these vaccines for managing SARS-CoV-2.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas Virais / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas Virais / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article